Pure Global's Brazil Brief: Decoding ANVISA's New AI Rules for MedTech Innovators.

In this episode, we dive into a critical regulatory update from Brazil that is sending shockwaves through the digital health community. Last week, ANVISA unexpectedly released a new instruction specifically targeting AI and Software as a Medical Device (SaMD), creating immediate hurdles for foreign manufacturers. We break down the three core changes involving clinical data, cybersecurity, and algorithm updates. This shift presents a major challenge for companies relying on international data and standard privacy protocols for their market entry. **Case In Point:** A German AI diagnostics firm, fully prepared for its Brazilian launch with a complete EU-validated data package, now faces a mandatory, year-long delay. They must initiate a new, costly local clinical study and re-engineer their data systems to comply with Brazil's specific privacy laws, jeopardizing their entire LATAM expansion strategy. **In this episode, you will learn:** * What are the specific new clinical data requirements for AI devices in Brazil? * How does Brazil's LGPD law now directly impact SaMD cybersecurity protocols? * Why might your existing FDA or CE mark for an AI device be insufficient for ANVISA? * What is the new, burdensome process for submitting simple algorithm updates? * Is it now impossible to enter the Brazilian market without local clinical trials? * Which types of SaMD are most affected by this surprise regulation? * What are the immediate steps you should take if you are planning a launch in Brazil? At Pure Global, we offer end-to-end regulatory consulting to help MedTech innovators navigate complex markets like Brazil. We combine local expertise with advanced AI tools to streamline global market access, from regulatory strategy and dossier submission to acting as your official in-country representative. To turn regulatory hurdles into market opportunities, contact us at [email protected] or visit https://pureglobal.com/.